-
Pharvaris B.V. NASDAQ:PHVS Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
Location: | Website: pharvaris.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
766.4M
Cash
343.6M
Avg Qtr Burn
-24.82M
Short % of Float
0.73%
Insider Ownership
9.49%
Institutional Own.
87.51%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Deucrictibant immediate-release capsules (PHVS416) Details Hereditary angioedema | Phase 3 Data readout | |
PHVS719 (deucrictibant extended-release tablets) Details Hereditary angioedema | Phase 3 Initiation | |
PHA121 Details Hereditary angioedema | Phase 2 Interim update | |
PHVS416 Details Hereditary angioedema | Phase 2 Update |